股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 延遲寄發通函 收購亞洲綜合細胞庫有限公司 25%已發行股本的 主要及關連交易 涉及根據特別授權 發行可換股票據 茲提述中基長壽科學集團有限公司（「本公司」）日期為二零二五年十二月一日的公 告，內容有關收購亞洲綜合細胞庫有限公司25%已發行股本的主要及關連交易涉及 根據特別授權發行可換股票據（「該公告」）。除非另外界定，本公告所用詞彙與該公 告所界定者具有相同涵義。 誠如該公告所披露，一份載有（其中包括）(i)目標公司、買賣協議及其項下擬進行的 交易之進一步資料；(ii)獨立董事委員會的推薦建議；(iii)獨立財務顧問就買賣協議 及其項下擬進行交易的條款而向獨立董事委員會及獨立股東發出的意見函件；(iv) 目標公司的財務資料；(v)上市規則規定 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Viewpoint - The company, Zhongji Changshou Science (00767), plans to acquire 25% of the issued share capital of Asia Comprehensive Cell Bank Limited for an initial consideration of HKD 300 million, with the option to issue up to HKD 300 million in non-redeemable convertible bonds to finance the acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, and will be financed through a combination of cash and convertible bonds [1] - Asia Comprehensive Cell Bank Limited specializes in high-end customized stem cell and IPSC storage services, catering primarily to high-net-worth individuals in Hong Kong and mainland China [1] Group 2: Business Operations - The target company operates under various trade names, including Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, employing a team of registered doctors and laboratory technicians [1] - The company provides preclinical immunotherapy services and testing, indicating a focus on advanced medical solutions [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a high-growth potential business area [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increasing consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, and proactive health management strategies [1]

Core Viewpoint - The company, Zhongji Changshou Science (00767.HK), has announced a conditional agreement to acquire a 25% stake in the target company, Zonghe Zhaoxue Cell Bank Limited, for an initial consideration of HKD 300 million, which will be adjusted as specified in the agreement [1] Group 1: Acquisition Details - The acquisition will be financed through the issuance of non-redeemable convertible bonds to the seller, with a maximum amount of HKD 300 million, thus not impacting the company's cash flow [1] - The acquisition is expected to generate positive cash flow for the company in the upcoming fiscal year 2026, based on profit guarantees [1] Group 2: Target Company Overview - The target company operates a premium customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to high-net-worth individuals, particularly in Hong Kong and China [1] - The target company conducts various medical tests, including patented high-standard early screening for circulating tumor cells and 21 other types of medical tests [1] - The target company is involved in research and development of novel cell-based preclinical immunotherapy, including natural killer cell therapies and umbilical cord-derived cell therapies [1] Group 3: Strategic Intent - The board is committed to improving the group's operational and financial conditions by actively seeking potential investment opportunities to diversify the existing business portfolio, expand revenue sources, and enhance shareholder value [2]

Core Viewpoint - Zhongji Changshou Science (00767) plans to acquire 25% of the issued share capital of Comprehensive Cell Bank Limited from China International Orthopedic Medical Group Co., Ltd. for an initial consideration of HKD 300 million, with the possibility of issuing redeemable convertible bonds up to HKD 300 million to finance this acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, with an initial payment of HKD 300 million [1] - The company will issue redeemable convertible bonds to cover the initial consideration, with a maximum amount of HKD 300 million [1] Group 2: Target Company Operations - The target company operates a boutique high-end customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to clients, particularly high-net-worth individuals in Hong Kong and mainland China [1] - The target company operates under the trade names of Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, staffed by registered doctors and laboratory technicians [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a new business area with significant growth potential [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increased consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, holistic health management, and proactive health management strategies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成購入、購買或認購本公司任何證券之邀請或要約。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 收購亞洲綜合細胞庫有限公司 25%已發行股本的 主要及關連交易 涉及根據特別授權 發行可換股票據 收購事項 董事會欣然宣佈，於二零二五年十二月一日（交易時段後），中國國際骨關節醫療 集團有限公司（「賣方」）（作為賣方）、本公司（作為買方）及閆立先生（「擔保人」） （作為擔保人）訂立買賣協議，據此，本公司有條件同意收購而賣方有條件同意出 售待售股份，佔亞洲綜合細胞庫有限公司（「目標公司」）已發行股本的25%，初始 代價為300,000,000港元（須按下文所述予以調整），並將根據特別授權向賣方發行 本金額最高達300,000,000港元的不可贖回可換股票據，藉此支付初始代價。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 ...

Core Viewpoint - The company Zhongji Changshou Science (00767) announced significant changes in its board of directors, effective from November 27, 2025 [1] Group 1: Board Changes - Mr. Li Si has resigned as an independent non-executive director and will no longer serve as the chairman of the audit committee, as well as a member of the remuneration committee, nomination committee, risk management committee, and share award committee [1] - Ms. Wang Huijuan has been appointed as an independent non-executive director and will serve on the audit committee, remuneration committee, nomination committee, risk management committee, and share award committee [1] - Mr. Huang Jiang has been appointed as the chairman of the audit committee [1]

Core Points - Zhongji Changshou Science (00767) announced changes effective from November 27, 2025, regarding its board of directors [1] Group 1: Board Changes - Mr. Li Si has resigned as an independent non-executive director and will no longer serve as the chairman of the audit committee, as well as a member of the remuneration committee, nomination committee, risk management committee, and share award committee [1] - Ms. Wang Huijuan has been appointed as an independent non-executive director and will serve on the audit committee, remuneration committee, nomination committee, risk management committee, and share award committee [1] - Mr. Huang Jiang has been appointed as the chairman of the audit committee [1]